Phase 1
N=34
A Multiple-Dose Study of LY3502970 in Healthy Participants
Healthy
Bottom Line
View on ClinicalTrials.gov: NCT05110794 ↗Enrolled (actual)
34
Serious AEs
0.0%
Results posted
May 2026
Primary outcome: Primary: PK: Maximum Observed Concentration (Cmax) of LY3502970 — 80.5; 67.5 nanograms per milliliter (ng/mL)
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 1
- Interventions
- LY3502970 (Drug)
- Age
- Adult, Older Adult · 21+ yrs
- Sex
- All
- Sponsor
- Eli Lilly and Company
- Primary completion
- Feb 2022
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY PK: Maximum Observed Concentration (Cmax) of LY3502970 |
80.5; 67.5 | — |
| PRIMARY PK: Area Under the Concentration-time Curve From 0 to 24 Hour (AUC0-24) of LY3502970 |
1200; 1050 | — |
| PRIMARY Time to Maximum Observed Concentration (Tmax) of LY3502970 |
8.0; 8.00 | — |
Summary
The main purpose of this study is to conduct blood tests to measure how much LY3502970 is in the bloodstream and how the body handles and eliminates LY3502970 in healthy participants in fed and fasted states. The study will also evaluate the safety and tolerability of LY3502970 in these participants. The study will last up to 49 days excluding the screening period.
Eligibility Criteria
Inclusion Criteria
- Are overtly healthy as determined by medical evaluation.
- Participants with body weight of 45 kilograms (kg) or more and body mass index (BMI) of 18.5 to 35.0 kilograms per meter squared (kg/m²).
Exclusion Criteria
- Participants who have an abnormal blood pressure and/or pulse rate, deemed to be clinically significant by the investigator at screening.
- Participants who used or intend to use over-the-counter (OTC) or prescription medication and/or herbal/vitamin/traditional medicines or mineral supplements that may affect the safety or objectives of the study, within 14 days prior to dosing and for the duration of the study. Paracetamol and Covid-19 vaccinations are permitted.
- Participants who are currently enrolled in a clinical study involving an investigational product (IP) or any other type of medical research judged not to be scientifically or medically compatible with this study.
- Participants who show evidence of human immunodeficiency virus (HIV) infection and/or positive HIV antibodies. A negative test within 6 months of screening would not need to be repeated.
- Participants who show evidence of hepatitis C and/or positive hepatitis C antibody. A negative test within 6 months of screening would not need to be repeated.
- Participants who show evidence of hepatitis B, positive hepatitis B surface antigen, and/or positive hepatitis B core antibody. A negative test within 6 months of screening would not need to be repeated.
Data sourced from ClinicalTrials.gov (NCT05110794). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.